The company's implantable system is the only long-term CGM that lasts up to 90 days; it is now available for $99 plus the cost of the sensor placement.
Senseonics, TypeZero and Roche Diabetes Care team-up to trial a long-term artificial pancreas system
The trial will integrate Senseonics' Eversense CGM System with TypeZero's inControl AP algorithms and Roche's Accu-Chek Insight Insulin Pump.
The system includes an implanted glucose sensor that lasts up to 90 days, a wearable smart transmitter to calculate glucose levels, and a mobile app.
The two companies aim to enable clinicians and patients to use the Diasend solution to review past CGM data along with insulin pump and activity tracker data.
The company has developed a pill-sized sensor that is entirely implanted in the user's upper arm from where it can continuously monitor their glucose levels.
The company makes a pill-like sensor that is entirely implanted in the user's upper arm from where it can continuously monitor glucose levels.
Senseonics raises additional $20 million of private equity financing, gets a new VP of Sales and Marketing
The company will use the fresh cash to complete pivotal trials in Europe, obtaining CE mark, and initiate IDE trials in the United States.